

March 28, 2025

WEGOVY CLINICAL PRIOR AUTHORIZATION CRITERIA REVISION IMPLEMENTS MAY 2, 2025

BACKGROUND

HHSC implemented the Wegovy (semaglutide) clinical prior authorization on Dec. 27, 2024. The Texas Drug Utilization Review Board prior authorization approved the criteria on Oct. 25, 2024.

KEY DETAILS

On May 2, 2025, HHSC will revise the Wegovy clinical prior authorization. Wegovy is approved for indication of risk reduction of major adverse cardiovascular events in adults with established cardiovascular disease only. The revised version will approve for the above indication if combined with reduced calorie diet and increased physical activity. The verification of the combination will be checked manually.